EX-99.1 2 exhibit991.htm EX-99.1 exhibit991
Baxter Stockholder Engagement Baxter International Inc. Fourth Quarter 2026


 
Forward-Looking Statements This presentation includes forward-looking statements concerning the company, including with respect to company’s strategic priorities, newly issued sustainability targets and certain regulatory matters. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company may be unable to successfully introduce or monetize new and existing products or services or keep pace with changing consumer preferences and needs or advances in technology; the company’s operating results and financial condition have fluctuated and may fluctuate in the future, which may constrain the company’s ability to achieve its financial and other goals; the company is exposed to risks as a result of its previously completed strategic actions; the company may not achieve the anticipated benefits of its significant transactions; the company has experienced in the past and may in the future experience manufacturing, sterilization, supply, or distribution difficulties; the effects of climate change, including legal, regulatory, or market measures related to climate change and other sustainability topics, could adversely affect the company’s business, results of operations, financial condition, and cash flows; the company’s goals, activities, and disclosures related to sustainability and corporate responsibility matters, and the perception of its activities in these areas, may fail to satisfy the differing expectations of key stakeholders on these matters; the company is subject to laws and regulations globally, and the company’s failure to comply with rapidly changing and increasingly divergent expectations of regulators in different jurisdictions could adversely impact the company; and other risks identified in the company's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements. 2


 
Use Of Non-GAAP Financial Measures To supplement Baxter’s consolidated financial statements presented on a U.S. GAAP basis, the company discloses certain non-GAAP financial measures. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. In addition, an explanation of the ways in which Baxter management uses these supplemental non-GAAP measures to evaluate its business and the substantive reasons why Baxter management believes that these non-GAAP measures provide useful information to investors is included in the company’s most recent earnings release filed with the SEC on Form 8-K on October 29, 2026. This information should be considered in addition to, and not as substitutes for, information prepared in accordance with U.S. GAAP. Baxter strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by the company may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP financial measures used in this presentation include organic sales growth and free cash flow. A reconciliation to comparable U.S. GAAP measures can be found herein. 3


 
Executive Summary 4 Management and Strategy Updates • Made progress on our turnaround effort during Andrew Hider’s first year as President and CEO, focused on three pillars: stabilizing the business, strengthening the balance sheet, and driving continuous improvement • Recently appointed John Rogers as CFO, who is a proven global medtech leader with broad transformation experience Board of Directors • In connection with the appointment of our CEO, enhanced the Board leadership structure by separating the CEO and Chair roles, with Brent Shafer serving as Non-Executive Chair of the Board • Continued focus on Board refreshment led to the appointment of three of our current independent directors over the last three years, with Michael McDonnell appointed to the Board and Audit Committee this past February Stockholder Outreach • Continued robust engagement with stockholders with key responsive actions taken over the last few years as stockholder feedback continues to be an important part of the Board’s longstanding commitment to furthering sound and effective corporate governance practices Executive Compensation • Thoughtfully designed compensation program constructed to align with Baxter’s performance, go-forward priorities, and commitment to creating long-term stockholder value Sustainability • Guided by our ongoing double materiality assessment, developed a new set of forward-looking targets and refined three focus areas: Deliver Sustainable Healthcare, Advance Climate and Resiliency, and Champion People and Communities • In 2025, established our inaugural Chief Sustainability Officer role to strengthen governance, coordination and accountability


 
Year One Under CEO Andrew Hider Stabilizing the business, strengthening the balance sheet, and driving a culture of continuous improvement 5 Progress Towards Turnaround Effort: Three Pillars1 1 Stabilizing the business • Raised full-year 2026 organic sales guidance2 to +3-4% • Combined Pharmaceuticals and Infusion Therapies under one segment to support stronger coordination, execution, and innovation • Discontinued manufacturing cephalosporin products at Round Lake, IL injectables facility to simplify operations and support greater supply resiliency of the remaining portfolio 2 Strengthening the balance sheet • Year-to-date free cash flow3 of $705 million reflects our focus on improving working capital and strengthening cash flow generation • Completed a $600 million cash tender offer, retiring $864 million of debt and accelerating deleveraging while supporting our investment-grade credit objectives • On track for ~3.0x net leverage target by year end 3 Driving continuous improvement • Implemented Baxter GPS (Growth & Performance System) across organization • GPS designed to enable a more disciplined operating model with greater visibility and accountability, and faster, data-driven decision making • 700+ improvement initiatives completed year-to-date; 200+ in flight 1. Non-GAAP financial metrics referenced in this slide include organic sales growth guidance and free cash flow. A reconciliation to comparable U.S. GAAP measures can be found herein. 2. Organic sales growth represents the company’s sales growth excluding the impact of the Kidney Care manufacturing and supply agreement (MSA) not reflected in reportable segments, impacts associated with business acquisitions or divestitures, and is calculated on a constant currency basis, as if foreign currency exchange rates had remained constant between the prior and current periods. 3. Operating cash flow less capital expenditures. Andrew Hider appointed President and CEO effective August 19, 2025 John Rogers appointed EVP and CFO effective October 1, 2026


 
Highly Experienced and Qualified Directors 6 Four of our current world-class directors have joined our Board since 2023 Key AC = Audit Committee; CTC = Compensation and Talent Committee; NCGPP = Nominating, Corporate Governance and Public Policy Committee; QRC = Quality and Regulatory Compliance Committee; * = Denotes committee chair Our directors have the relevant skills and expertise to provide effective oversight Robust Board Refreshment The Board believes in the importance of maintaining a balance of fresh perspectives and significant institutional knowledge, with the size fixed between seven to twelve members We welcomed a new Director to the Board in 2026 • As part of our thoughtful approach to Board composition, we welcomed Michael McDonnell to the Board and the Audit Committee in February • Michael brings decades of CFO experience across major global life sciences and technology companies, including most recently as CFO at Biogen We value periodic Committee leadership rotation • William Ampofo assumed the role of Quality and Regulatory Compliance Committee Chair in May 2026 • Patricia Morrison became the Nominating, Corporate Governance and Public Policy Committee Chair earlier this year M&A / Transactional Expertise 78% Financial Expertise 89% Andrew Hider President & CEO, Baxter Brent Shafer Non-Executive Chair Former Chair and CEO, Cerner Corporation Committee: NCGPP Jeffrey (Jay) A. Craig Former CEO and President, Meritor Committees: AC*, CTC Michael R. McDonnell Former EVP and CFO, Biogen Committee: AC Nancy M. Schlichting Former President and CEO, Henry Ford Health System Committees: CTC*, QRC Amy A. Wendell Former SVP, Strategy and Business Development, Covidien Committees: CTC, QRC Patricia B. Morrison Former EVP, Customer Support Services & CIO, Cardinal Health Committees: AC, NCGPP* David S. Wilkes, M.D. Former Dean of the University of Virginia School of Medicine, CSO and Co-Founder, ImmuneWorks Committees: NCGPP, QRC Healthcare Marketing Expertise 67% William A. Ampofo II SVP, Parts & Distribution Services and Supply Chain, Boeing Global Services Committee: QRC* Joined in 2023 Joined in 2026Joined in 2024 Joined in 2025


 
Extensive Stockholder Engagement Program 7 Strong record of stockholder engagement and responsiveness: in 2025, we contacted holders representing ~68% of shares and held engagements with holders of ~61% of shares Topics discussed Company strategy and performance Corporate governance Board composition Management succession planning Board leadership structure Executive compensation Stock ownership guidelines Sustainability Demonstrated responsiveness to stockholders  Expanded proxy disclosure on Board refreshment, succession planning, and executive compensation  Amended the Stock Ownership Guidelines to implement additional stock retention requirements  Adopted executive cash severance policy limiting NEO cash severance benefits  Separated the CEO and Chair roles  Refreshed our Code of Conduct, including adding responsible use of AI Statistics calculated based on shares outstanding as of Dec. 31, 2025.


 
8% 12% 20% 20% 40% 2025 Executive Compensation Aligned With Strategic Priorities 8 Pay Element Vehicle Objectives Base Salary Cash • Provides a base level of competitive compensation to attract and retain executive talent Annual Incentive Cash • Motivates and rewards executives for company and individual performance against annually established financial targets and individual objectives • Based on Adjusted Net Sales (50%), Adjusted EPS (25%) and Free Cash Flow (25%) • Individual performance assessment measured based on People (50%) and Quality (50%); expressed as a percentage ranging from 0% to 125% Long Term Incentive Stock Options 25% of LTI • Motivates and rewards NEOs consistent with the company’s long-term objectives and increasing stockholder value • No value realized unless the stock price appreciates above the grant price • Vests ratably over three-year period Restricted Stock Units (RSUs) 25% of LTI • Motivates and rewards NEOs consistent with the company’s long-term objectives and increasing stockholder value • Vests ratably over three-year period Performance Share Units (PSUs) 50% of LTI • Motivates and rewards NEOs for company performance against financial targets • Recognizes that a portion of at least 50% of an NEO’s equity awards should be completely “at-risk,” measured over the three-year performance period • Based on Adjusted ROIC (50%) and Adjusted Net Sales CAGR (50%) • Relative TSR modifier (80%, 100% or 120% applied) against companies in the S&P 500 Healthcare Equipment & Services Index1 CEO Target Pay Mix (2025)2 92% Performance Based Stock Options Base Salary Annual Incentive PSUs RSUs 80% Long-Term 1. Actual payout for 2025 PSUs cannot exceed 200% of target. 2. Reflects Andrew Hider’s 2025 target pay mix; percentages are calculated using annual base salary, target annual incentive and target annual LTI grant values as of December 31, 2025.


 
Targets Core Pillars & Strategic Topics: Advancing Patient Care while Protecting the Planet and Strengthening Communities 9 Climate and Resiliency Sustainable Healthcare People and Communities Delivering sustainable healthcare is core to our Mission to Save and Sustain Lives • Patient Safety and Product Quality • Sustainable Products and Innovation • Sustainable Packaging • Data Security and Privacy Minimizing environmental impact and building resilient operations remain central responsibilities of our sustainability program • Climate Change • Water Stewardship • Supply Chain Management Culture shaped by our people and their engagement, within the workplace and across communities where we live, work and serve • Employee Experience • Employee Health and Safety • Community Investment Net-Zero Scope 1 and Scope 2 GHG emissions by 2050, 1.5°C-aligned 100% renewable electricity by 2040 80% of supplier spend in priority categories have science-based targets by 2030 100K volunteer hours by 2031 (baseline 2026) $275M investment in underserved communities by 2030 (baseline 2021)


 
Non-GAAP Reconciliations Baxter International Inc.


 
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES Non-GAAP Reconciliations: In this presentation, Baxter used non-GAAP financial measures of sales growth (on an organic basis) and free cash flow. The reconciliations set forth below reconcile the non-GAAP measures set forth in this presentation for historical periods to the most directly comparable U.S. GAAP measures. 11 Projected Full Year 2026 U.S. GAAP Sales Growth to Projected Organic Sales Growth (unaudited) Sales Growth Guidance FY 2026* Sales growth - U.S. GAAP 4% - 5% Kidney Care MSA ~30 bps Foreign Exchange (~100 bps) Organic sales growth 3% - 4% Operating Cash Flow to Free Cash Flow (unaudited) (in millions) Nine Months Ended September 30, 2026 Cash flows from (used in) operations - continuing operations $ 1,068 Cash flows from (used in) investing activities - continuing operations (360) Cash flows from (used in) financing activities (662) Cash flows from (used in) operations - continuing operations $ 1,068 Capital expenditures - continuing operations (363) Free cash flow - continuing operations $ 705 *Totals may not add across due to rounding Change in organic sales growth and free cash flow are non-GAAP measures. For more information on the company's use of non-GAAP financial measures in this presentation, please see the company's Current Report on Form 8-K filed with the Securities Exchange Commission on the date of this presentation.